PROF. ZHILING YU APPOINTED AS CO-EDITOR-IN-CHIEF OF TRENDS IN IMMUNOTHERAPY

We are pleased to announce that Prof. Zhiling Yu has been appointed Co-Editor-in-Chief of Trends in Immunotherapy(ISSN: 2573-5985). His term started in March 2023. 

Prof. Yu received his obtained his PhD degree in biochemistry from the Hong Kong University of Science and Technology. Before joining the Hong Kong Baptist University, Prof. Yu once worked at China Pharmaceutical University, Nagasaki University, Hong Kong University of Science and Technology, Xiamen University and University of Macau. Prof. Yu is known for his research in herbal pharmacology, and in processing of Chinese medicinal materials. He has published more than 200 peer-reviewed research papers with h = 40.

Consun Pharmaceutical Group Limited and Laboratory Jane Clare Limited in collaboration with Prof. Yu's team established "Consun Chinese Medicines Research Centre for Renal Diseases" and "Jane Clare Transdermal TCM Therapy Laboratory", respectively, in Hong Kong Baptist University.

Prof. Yu serves as Editorial Board Member/Associate Editor/Executive Editor/ Consulting Editor for more than 30 journals, e.g.  LiShizhen Medicine and Materia Medica Research, BMC Complementary Medicine and Therapies, Current Topics in Nutraceutical ResearchJournal of Alternative, Complementary & Integrative MedicinePharmacological Research.

The TI editorial team warmly welcomes Prof. Zhiling Yu as the Co-Editor-in-Chief and looks forward to his contribution to the continued success of Trends in Immunotherapy.